Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2019.02.079
Abstract: BACKGROUND The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial showed that the combination of low-dose rivaroxaban and aspirin reduced major vascular events in patients with stable vascular disease. OBJECTIVES The purpose of this… read more here.
Keywords: rivaroxaban aspirin; risk; trial; patients treated ... See more keywords
Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cardiovascular Pharmacology"
DOI: 10.1097/fjc.0000000000001382
Abstract: Abstract: Dual pathway inhibition (DPI) with low-dose rivaroxaban and aspirin in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD) reduces the occurrence of cardiovascular (CV) events; however, the underlying mechanisms explaining these… read more here.
Keywords: pathway inhibition; pathway; dual pathway; rivaroxaban aspirin ... See more keywords
Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Applied Thrombosis/Hemostasis"
DOI: 10.1177/10760296211073922
Abstract: Background The COMPASS trial demonstrated that in patients with peripheral arterial disease, the combination of rivaroxaban and aspirin compared with aspirin reduces the risk of major adverse limb events, but it is not known whether… read more here.
Keywords: claudication; arterial disease; rivaroxaban aspirin; peripheral arterial ... See more keywords